{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-411298","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2026-10-02T12:05:48+00:00","discovered_at":"2026-10-02T12:10:00.317056+00:00","generated_at":"2026-10-12T14:31:46.025728+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Surrozen wins FDA clearance for SZN-8141 IND; $95.1M second closing milestone triggered","bullets":["FDA cleared Surrozen's IND for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody given as an intravitreal injection for diabetic macular edema (DME).","First patient dosing in the Phase 1b/2a DUET study in DME expected in Q4 2026, with initial data expected in the second half of 2027.","IND clearance satisfies the second closing milestone of the March 2025 two-tranche private placement; ~$95.1M in gross proceeds expected on or about October 20, 2026.","Proceeds will support SZN-8141, SZN-8143 and broader operations; an S-3 resale registration must be filed within 30 days of closing.","Surrozen also plans to develop SZN-8141 in neovascular age-related macular degeneration and is evaluating other retinal vascular diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-411298","json":"https://secwatch.observer/filing/0001193125-26-411298.json","markdown":"https://secwatch.observer/filing/0001193125-26-411298.md","text":"https://secwatch.observer/filing/0001193125-26-411298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/0001193125-26-411298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/srzn-20261002.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:31:46.025728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}